{"name":"Array Biopharma, now a wholly owned subsidiary of Pfizer","slug":"array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ARRY-142886, MEK inhibitor; oral","genericName":"ARRY-142886, MEK inhibitor; oral","slug":"arry-142886-mek-inhibitor-oral","indication":"Solid tumors","status":"phase_1"},{"name":"ARRY-300, MEK inhibitor; oral","genericName":"ARRY-300, MEK inhibitor; oral","slug":"arry-300-mek-inhibitor-oral","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"ARRY-382, cFMS inhibitor; oral","genericName":"ARRY-382, cFMS inhibitor; oral","slug":"arry-382-cfms-inhibitor-oral","indication":"Solid tumors","status":"phase_1"},{"name":"ARRY-438162, MEK inhibitor; oral","genericName":"ARRY-438162, MEK inhibitor; oral","slug":"arry-438162-mek-inhibitor-oral","indication":"Metastatic non-small cell lung cancer","status":"phase_2"}]}],"pipeline":[{"name":"ARRY-142886, MEK inhibitor; oral","genericName":"ARRY-142886, MEK inhibitor; oral","slug":"arry-142886-mek-inhibitor-oral","phase":"phase_1","mechanism":"MEK inhibitor","indications":["Solid tumors"],"catalyst":""},{"name":"ARRY-300, MEK inhibitor; oral","genericName":"ARRY-300, MEK inhibitor; oral","slug":"arry-300-mek-inhibitor-oral","phase":"phase_1","mechanism":"MEK inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"ARRY-382, cFMS inhibitor; oral","genericName":"ARRY-382, cFMS inhibitor; oral","slug":"arry-382-cfms-inhibitor-oral","phase":"phase_1","mechanism":"cFMS inhibitor","indications":["Solid tumors"],"catalyst":""},{"name":"ARRY-438162, MEK inhibitor; oral","genericName":"ARRY-438162, MEK inhibitor; oral","slug":"arry-438162-mek-inhibitor-oral","phase":"phase_2","mechanism":"Inhibits MEK, a protein involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPNVNGWHRnUFRYeUlCUm1xM1k1R3UtOHhDYXE4MUlacHRvVjQ5anJSbGxudEhkbVYzRloyaWhPVzh1WUljWm1KSnIzVlpsaXRTS3VIdC1SaXhwQTJhYjFRR2NFSDhFTXIxNDV5OGNuOWpfSGRaZ3BjWnBLLTFtaC1Zeg?oc=5","date":"2024-02-05","type":"deal","source":"Fierce Pharma","summary":"The top 10 biopharma M&A deals of 2023 - Fierce Pharma","headline":"The top 10 biopharma M&A deals of 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9pMHpmWV92QnJQTDh6aGMwclpuMTdvTDdYNzlSOHVzYmZtRllzT3RxWlhSRHNpcXZ2eDZSbWVuMElhQ2VScmdmbVFCWDZLZ3p3d2xiM0pTcnRUQTlXZ1R3T0tMNHhjRGpWcWZPVFpjcw?oc=5","date":"2021-12-14","type":"pipeline","source":"Investopedia","summary":"Pfizer’s Top 7 Acquisitions: Warner-Lambert, Wyeth, and More - Investopedia","headline":"Pfizer’s Top 7 Acquisitions: Warner-Lambert, Wyeth, and More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPLTBPQ2wwRm53MVk5elFDdGZxT0F4YW8wWmdpTnRoQjhvOFVka1p4eHFITEk1M1pycDdhQzZQa0xlVjZ4MzJGVjBjYzl0U3o5QnA1bFJOTmFhVUR4dk9QRHJsUkVjakRTbXlPYnJ6R3JsNVFZWFo0Z3pMdVZxcUFXVV96SFRPNk1GaUk4QVdsT0t3Nm5LcmhmZjVIVXV3MDVzSy1ZcXJDVmk?oc=5","date":"2020-10-05","type":"pipeline","source":"BioPharma Dive","summary":"With a sweetened offer, BridgeBio plans to reel in a subsidiary - BioPharma Dive","headline":"With a sweetened offer, BridgeBio plans to reel in a subsidiary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQVi05M3NrZk9qb1FIcE01OFJUWURVWWRQRHRBLTd0OWpzQUFteU5ibk5qLXVydG0xaG1BLVNuR0lBSHZJbWlOY3ZBQnpqTGdZZHBIU09NZmpUYnRFSkpOSHZqU0d0c3ZNQVE3ZTBUdjVuaW9TZjlfTURXN3Zac2ZQQ3lNYTJoZTNFNDI5dW1ZSVhyT1JqdlowbkhKZ2twTkVEaGNMOGRoZ0tyWXQtRG82TjBMRWJCUjA?oc=5","date":"2020-01-22","type":"deal","source":"European Pharmaceutical Review","summary":"The biggest pharma merger and acquisition deals of 2019 - European Pharmaceutical Review","headline":"The biggest pharma merger and acquisition deals of 2019","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPLUZqblF0Mld0U1BDb1VJZjcxWER2aXVnQ2dLYml3dklLRXFyNmhSNGRsaFhEVjRDVHRvMTFta3l5VVZaR1FiOElBa2dDeDFVcVFvSGNZdlBYV2w0NU9sX3pGSjlmZUhKSTB6bmJEMkhhbHZ6ZlJsbVJEano4dFEyR08yMjkxZ1VCa2NN?oc=5","date":"2020-01-06","type":"deal","source":"Fierce Pharma","summary":"The top 10 largest biopharma M&A deals in 2019 - Fierce Pharma","headline":"The top 10 largest biopharma M&A deals in 2019","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQRE9zQ1JQZEczOTNnZHJXamRKY18tTnU1UUtMUjB3WjJWb3V5QTg2ekc2V2JRMlJqdVpfT0EwdDQ1SHg5UXlncC02QjQ2RnNvUWVpeWMteDl3SXNteFlIdlg2ZlpFMzFHTDZaX01yNVFuUlVhQ0xGdnRvT2s3VVZlSl84eXB6QmtScGtZVWp6NE9HWFVBczlhQXI1MA?oc=5","date":"2019-08-07","type":"pipeline","source":"BioPharma Dive","summary":"Lilly shuffles executives overseeing oncology and M&A - BioPharma Dive","headline":"Lilly shuffles executives overseeing oncology and M&A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQX3p0MzhteUQ2eUt2azFzX1NCMHFid0FReHhqbDF0c2IteW5VM3NmU2xlcVZDYWNaSGVzZEx2U1VfcUhoLW1YLUhTV0oyMWRuTGpWeUxrVXZiZnhvSGhRZnhHRGxxalo3RERmMkt1QWRmTkt1YlBub2JWYkd2dS13bXBpVDMwR0xOUVBYck44amw2T3JJTnNKc1RILUpOb2NtN1pBYw?oc=5","date":"2019-06-17","type":"deal","source":"Fierce Pharma","summary":"Pfizer, 'never say never' with big M&A, inks $11.4B Array cancer deal - Fierce Pharma","headline":"Pfizer, 'never say never' with big M&A, inks $11.4B Array cancer deal","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":3,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}